BIIB113
/ Biogen
- LARVOL DELTA
Home
Next
Prev
1 to 8
Of
8
Go to page
1
February 12, 2025
Trimmed pipeline
(Firstwordpharma Press Release)
- "Alongside its fourth-quarter results, Biogen said that as part of ongoing pipeline prioritisation efforts, it has discontinued development of: BIIB113 in early Alzheimer's disease; BIIB094 in early Parkinson's disease; BIIB101 in multiple system atrophy; and BIIB143 (cemdomespib) in diabetic peripheral neuropathic pain."
Discontinued • Alzheimer's Disease • Diabetic Neuropathy • Multiple System Atrophy • Parkinson's Disease • Peripheral Neuropathic Pain
March 04, 2024
Biogen Highlights New Data at the International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD) 2024 Annual Meeting
(GlobeNewswire)
- "Biogen Inc...announced it will present new data from its Alzheimer’s disease (AD) portfolio at the upcoming International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD 2024), taking place March 5-9 in Lisbon, Portugal and virtually. The presentations include new data for its oral small molecule inhibitor of tau aggregation (BIIB113)....Biogen presentations will provide new data on brain target engagement and the safety profile in healthy volunteers of an oral small molecule O-GlcNAcase (OGA) enzyme inhibitor intended to reduce tau aggregation (BIIB113). In addition to BIIB113, Biogen is researching the potential of tau reduction in AD with its investigational antisense oligonucleotide targeting the microtubule associated protein tau (MAPT) gene (BIIB080). Other presentations will discuss the long-term efficacy of lecanemab..."
Clinical data • Alzheimer's Disease • CNS Disorders
February 16, 2024
OCCUPANCY OF BIIB113, AN INHIBITOR OF THE ENZYME O-GLCNACASE (OGA) IN THE HUMAN BRAIN.
(ADPD 2024)
- "We have demonstrated a high-level of brain TO (>90%) following single and multiple doses of BIIB113 in HV. These results support continued clinical development of BIIB113 in Phase 2 studies and will support the selection of dose regimens."
Alzheimer's Disease • CNS Disorders • OGA
February 16, 2024
RESULTS OF THE FIRST-IN-HUMAN, RANDOMIZED, BLINDED, PLACEBO-CONTROLLED, SINGLE- AND MULTIPLE- ASCENDING DOSE STUDY OF BIIB113 IN HEALTHY VOLUNTEERS
(ADPD 2024)
- P1 | "BIIB113 demonstrated an acceptable safety and PK profile following single and multiple doses of BIIB113 in HV. These results support continuing clinical development of BIIB113 in Phase 2 for patients with AD."
Clinical • P1 data • Alzheimer's Disease • CNS Disorders • OGA
February 04, 2024
Biogen to Realign Resources for Alzheimer's Disease Franchise
(GlobeNewswire)
- "Biogen Inc...today announced plans to reprioritize its resources in Alzheimer’s disease (AD)....The company will continue to advance LEQEMBI (lecanemab-irmb), the first anti-amyloid beta treatment with FDA traditional approval in the United States, and will accelerate development of potential new treatment modalities, including its ASO targeting tau (BIIB080) and an oral small molecule inhibitor of tau aggregation (BIIB113). The company will discontinue the development and commercialization of ADUHELM (aducanumab-avwa) 100 mg/mL injection for intravenous use and will terminate the ENVISION clinical study....Biogen licensed aducanumab from Neurimmune and has terminated that license. The rights to aducanumab will revert to Neurimmune."
Discontinued • Licensing / partnership • Pipeline update • Alzheimer's Disease • CNS Disorders
July 18, 2023
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics, With Target Occupancy Study of BIIB113 in Healthy Participants
(clinicaltrials.gov)
- P1 | N=73 | Completed | Sponsor: Biogen | Recruiting ➔ Completed | N=105 ➔ 73
Enrollment change • Trial completion • OGA
October 28, 2022
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics, With Target Occupancy Study of BIIB113 in Healthy Participants
(clinicaltrials.gov)
- P1 | N=105 | Recruiting | Sponsor: Biogen | Trial completion date: Mar 2023 ➔ Jul 2023 | Trial primary completion date: Dec 2022 ➔ Jul 2023
Trial completion date • Trial primary completion date • OGA
March 22, 2022
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics, With Target Occupancy Study of BIIB113 in Healthy Participants
(clinicaltrials.gov)
- P1 | N=105 | Recruiting | Sponsor: Biogen | Not yet recruiting ➔ Recruiting | Trial completion date: Dec 2022 ➔ Mar 2023
Enrollment open • Trial completion date • OGA
1 to 8
Of
8
Go to page
1